Comparing BioAmber (BIOA) & Its Rivals
BioAmber (NYSE: BIOA) is one of 52 publicly-traded companies in the “Specialty Chemicals” industry, but how does it weigh in compared to its competitors? We will compare BioAmber to similar companies based on the strength of its analyst recommendations, risk, dividends, valuation, profitability, earnings and institutional ownership.
Insider & Institutional Ownership
37.4% of BioAmber shares are owned by institutional investors. Comparatively, 69.9% of shares of all “Specialty Chemicals” companies are owned by institutional investors. 8.3% of BioAmber shares are owned by company insiders. Comparatively, 7.1% of shares of all “Specialty Chemicals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares BioAmber and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and recommmendations for BioAmber and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioAmber currently has a consensus target price of $3.00, indicating a potential upside of 525.00%. As a group, “Specialty Chemicals” companies have a potential upside of 5.15%. Given BioAmber’s higher possible upside, equities analysts plainly believe BioAmber is more favorable than its competitors.
Risk and Volatility
BioAmber has a beta of 2.7, suggesting that its share price is 170% more volatile than the S&P 500. Comparatively, BioAmber’s competitors have a beta of 1.58, suggesting that their average share price is 58% more volatile than the S&P 500.
Valuation and Earnings
This table compares BioAmber and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|BioAmber||$10.54 million||-$24.98 million||-0.60|
|BioAmber Competitors||$1.95 billion||$301.80 million||16.43|
BioAmber’s competitors have higher revenue and earnings than BioAmber. BioAmber is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
BioAmber competitors beat BioAmber on 9 of the 12 factors compared.
BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.
Receive News & Stock Ratings for BioAmber Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAmber Inc. and related stocks with our FREE daily email newsletter.